ARRA ^ Clinical Studies of Vaccines for Pandemic H1N1 Influenza

ARRA ^ 大流行性 H1N1 流感疫苗的临床研究

• 批准号: 7964773
• 负责人: Kanta Subbarao
• 金额: $ 4.23万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7964773
• 关键词: American; Attenuated; Attenuated Live Virus Vaccine; Avian Influenza A Virus; Biological Assay; California; Centers for Disease Control and Prevention (U.S.); Clinical Research; Clinical Trials; Disease; Equilibrium; Family suidae; Gene Combinations; Gene Proteins; Genes; Genetic; Goals; Hemagglutination; Hemagglutinin; Human; Immune response; Infection; Influenza; Influenza A Virus, H1N1 Subtype; Licensing; Life; Membrane Glycoproteins; Neuraminidase; Porcine Influenza A Virus; Reporting; Simian B disease; United States; Vaccines; Virus; Virus Diseases; World Health Organization; attenuation; base; genetic analysis; immunogenicity; influenza virus vaccine; novel; pandemic disease; pandemic influenza; pandemic preparedness; preclinical study; programs; response; vaccine candidate; vaccine development

An appropriate vaccine is essential for a global pandemic preparedness and response. Hemagglutination inhibition assays reveal that the 2009 pandemic H1N1 viruses are antigenically homogeneous and distinct from currently circulating seasonal H1N1 viruses. Based on antigenic and genetic analysis and epidemiologic information, the WHO selected the A/California/7/2009 (H1N1) virus as the reference virus for vaccine development. We will evaluate the immunogenicity and infectivity of the live attenuated reassortant H1N1 virus containing the surface glycoproteins from the California/7/2009 (H1N1) virus and internal protein genes from the A/Ann Arbor/6/60 cold-adapted (ca) virus in clinical trials.

适当的疫苗对于全球大流行病的防范和应对至关重要。血凝抑制试验表明，2009年大流行性H1N1病毒的抗原性是同质的，不同于目前流行的季节性H1N1病毒。根据抗原和遗传分析以及流行病学信息，世卫组织选择A/加州/7/2009（H1N1）病毒作为疫苗开发的参考病毒。我们将在临床试验中评价含有来自加州/7/2009（H1N1）病毒的表面糖蛋白和来自A/安阿伯/6/60冷适应（ca）病毒的内部蛋白基因的减毒活疫苗H1N1病毒的免疫原性和感染性。